176 related articles for article (PubMed ID: 35344588)
1. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
[TBL] [Abstract][Full Text] [Related]
2. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
4. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
6. A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
Luo L; Ramanathan R; Horlbogen L; Mathialagan S; Costales C; Vourvahis M; Holliman CL; Rodrigues AD
Anal Chem; 2020 Jul; 92(14):9745-9754. PubMed ID: 32551505
[TBL] [Abstract][Full Text] [Related]
7. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
8. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
9. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
11. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
14. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.
Wang X; Purohit V; Dowty ME; Rodrigues D; Luo L; Mathialagan S; Carey W; Plotka A; Kalluru H; Melissa O; Kaplan J; Huh Y; Vourvahis M; Wolk RM
J Clin Pharmacol; 2023 Jul; 63(7):784-797. PubMed ID: 36807251
[TBL] [Abstract][Full Text] [Related]
17. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
Choi H; Huang F; Flack M
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy Increases the Renal Secretion of N
Bergagnini-Kolev MC; Hebert MF; Easterling TR; Lin YS
Drug Metab Dispos; 2017 Mar; 45(3):325-329. PubMed ID: 28069720
[TBL] [Abstract][Full Text] [Related]
20. The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics.
Shi B; Zhang Y; Huang B; Lin H; Zhou Q; Wang Y; Cai Z; Liu M
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
